Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Takeda Pharmaceutical ADR Rep 0.5 Ord Shs TAK

Takeda Pharmaceutical Company Limited is a Japan-based company mainly engaged in the pharmaceutical business. The Company is engaged in the research, development, manufacture and sale of pharmaceutical products, General medical products, quasi drugs and healthcare products in Japan and overseas. The Company's research and development functions are concentrated in four areas of oncology (cancer)... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >

Current News (NYSE:TAK)

HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda

GlobeNewswire 7 days ago

Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer

Business Wire 7 days ago

Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder

PR Newswire 10 days ago

Takeda, Astellas and Sumitomo Mitsui Banking Announce Master Agreement to Establish Joint Venture Company for Incubation of Early Drug Discovery Programs

PR Newswire 11 days ago

U.S. FDA Approves Subcutaneous Administration of Takeda's ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn's Disease

Business Wire April 18, 2024

Takeda Announces New U.S. Corporate Social Responsibility Program Partners to Build Equity through STEM Education and Access to Nutritional Food

Business Wire April 8, 2024

Empathy in Action: Takeda's Global Initiative Brings IBD Challenges to the Forefront in the UAE

PR Newswire March 27, 2024

Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting

Business Wire March 26, 2024

Takeda Announces Approval of ADZYNMA® Intravenous Injection 1500 (apadamtase alfa /cinaxadamtase alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

Business Wire March 26, 2024

Opinion & Analysis (NYSE:TAK)

No current opinion is available.

Bullboard Posts (NYSE:TAK)

Real stock price share value

4226$
Nibinator - November 14, 2023

colchicine vs covid

We got a new credible study out of Quebec. This drug is preventing: hospitalizations by 25%, the need for mechanical ventilation by 50%,...
GoldBrooke - January 25, 2021

Healthcare Stocks to Watch

There is a wide array of offerings from innovative care to advanced digital technologies from every corner of the market assessing just...
SHFeatureArticl - February 28, 2020